Loading...

PRME - Prime Medicine, Inc.

Analyst Downgrade Signal for 01-16-2024
Analyst Downgrade Signal: PRME from Buy to Hold by Stifel
Price Target: $18>>9


Loading Chart PRME

Stock Signal Information


Signal

Analyst Downgrade Signal: PRME from Buy to Hold by Stifel
Price Target: $18>>9
Report Date: 01-16-2024
Symbol: PRME - Prime Medicine, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Downgrade Signal: PRME from Buy to Hold by Stifel
Price Target: $18>>9

  PRME Technical Analysis

Company Contact

Prime Medicine, Inc. (PRME)
21 Erie Street
Cambridge, MA 02139
Phone: 617-564-0013
Website: https://www.primemedicine.com
CEO: Dr. Keith Michael Gottesdiener M.D., Ph.D.

PRME, Prime Medicine, Inc.

PRME Prime Medicine, Inc. Logo Image

NASDAQ, NASDAQ Global Market


Company Profile

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.